Biotech Decliners: Genocea Biosciences Inc (NASDAQ:GNCA), Aratana Therapeutics Inc (NASDAQ:PETX), Oncothyreon Inc (NASDAQ:ONT), Actinium Pharmaceuticals Inc (NYSEMKT:ATNM), ImmunoGen (NASDAQ:IMGN)

Genocea Biosciences Inc (NASDAQ:GNCA), a clinical-stage biopharmaceutical company developing T cell-enabled vaccines and immunotherapies, announced positive top-line results from a Phase 1 study of GEN-004, an investigational vaccine candidate designed to prevent infections from all serotypes of pneumococcus (Streptococcus pneumoniae), a major cause of infectious disease-related death globally. The Phase 1 study met its safety, tolerability and immunogenicity goals, including measurable increases in the blood of T helper 17 (TH17) cells, a rare cell type that provides immunity at epithelial and mucosal surfaces. Based on these data, the Company plans to advance GEN-004 into a Phase 2a trial in the third quarter of 2014.Genocea Biosciences Inc (NASDAQ:GNCA) weekly performance is 1.38%. On last trading day company shares ended up $19.16. Analysts mean target price for the company is $28.00. Genocea Biosciences Inc (NASDAQ:GNCA) distance from 50-day simple moving average is 0.79%.

Aratana Therapeutics (NASDAQ: PETX) announced the appointment of former Cephalon, Inc., executive Robert P. Roche, Jr. to its Board of Directors. Mr. Roche has extensive operational and product launch expertise working for leading pharmaceutical companies.Aratana Therapeutics Inc (NASDAQ:PETX) shares fell -5.43% in last trading session and ended the day on $14.79. PETX Gross Margin is 66.70% and its return on assets is -13.90%. Aratana Therapeutics Inc (NASDAQ:PETX) quarterly performance is -21.54%.

Celldex Therapeutics, Inc (NASDAQ:CLDX) announced that the company has entered into a collaboration agreement with Oncothyreon Inc (USA) (NASDAQ:ONT). The announcement was made on May 30. 2014. Both the above mentioned companies will collaborate on the combined clinical trial of Varlilumab (CDX-1127) and ONT-10. This Phase lb trial will be an open label study where the ONT-10 will be observed as the recommended single agent dose combined with varlilumab at 2 dose level for patients suffering with ovarian or breast cancer. Oncothyreon Inc (USA) (NASDAQ:ONT) shares moved down -6.29% in last trading session and was closed at $3.28, while trading in range of $3.23-$3.51. Oncothyreon Inc (USA) (NASDAQ:ONT) year to date performance is 86.36%.

Actinium Pharmaceuticals Inc (NYSEMKT:ATNM) announced that it has priced public offering of 1.67 million shares of its common stock at a price to the public of $7.50 per share.Actinium Pharmaceuticals Inc (NYSEMKT:ATNM) ended the last trading day at $7.09. Company weekly volatility is calculated as 10.89% and price to cash ratio as 30.72. Actinium Pharmaceuticals Inc (NYSEMKT:ATNM) showed a negative weekly performance of -31.50%.

Immunogen (NASDAQ:IMGN) has earned an average rating of “Buy” from the thirteen brokerages that are presently covering the stock. Two analysts have rated the stock with a sell rating, two have issued a hold rating and eight have given a buy rating to the company. ImmunoGen, Inc. (NASDAQ:IMGN) weekly performance is -8.44%. On last trading day company shares ended up $12.04. Analysts mean target price for the company is $17.45. ImmunoGen, Inc. (NASDAQ:IMGN) distance from 50-day simple moving average is -2.52%.